Ciba Vision/Presby Corp.
This article was originally published in The Gray Sheet
Exclusive worldwide license is granted to Ciba Vision to manufacture and market Presby's scleral expansion implants and specialized automated incision device for presbyopia, ocular hypertension and primary open angle glaucoma. Ciba will provide additional cash infusions to Presby in conjunction with future milestones, including FDA approval for glaucoma and presbyopia, expected in two and three years, respectively. Ciba Vision anticipates a launch in Europe and Canada later this year...
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.